Kronos Bio (KRON)
(Delayed Data from NSDQ)
$0.76 USD
-0.21 (-22.09%)
Updated May 24, 2024 03:59 PM ET
After-Market: $0.78 +0.02 (3.22%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Kronos Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 173 | 238 | 340 | 413 | 92 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 6 | 8 | 7 | 1 |
Total Current Assets | 179 | 244 | 348 | 420 | 93 |
Net Property & Equipment | 10 | 13 | 15 | 14 | 4 |
Investments & Advances | 2 | 10 | 0 | 49 | 5 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 3 | 2 | 2 | 0 |
Total Assets | 213 | 295 | 391 | 512 | 103 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 5 | 1 | 5 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 13 | 9 | 5 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 10 | 1 | 1 | 2 | 0 |
Total Current Liabilities | 25 | 21 | 14 | 13 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 4 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1 | 2 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 54 | 50 | 46 | 46 | 3 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 123 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 668 | 641 | 608 | 577 | 0 |
Retained Earnings | -509 | -396 | -263 | -112 | -23 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 159 | 245 | 345 | 466 | 100 |
Total Liabilities & Shareholder's Equity | 213 | 295 | 391 | 512 | 103 |
Total Common Equity | 159 | 245 | 345 | 466 | -23 |
Shares Outstanding | 58.30 | 56.90 | 56.30 | 56.00 | NA |
Book Value Per Share | 2.73 | 4.30 | 6.13 | 8.31 | 0.00 |
Fiscal Year End for Kronos Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 152 | 173 | 187 | 219 | 226 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 6 | 5 | 5 | 6 |
Total Current Assets | 158 | 179 | 192 | 224 | 232 |
Net Property & Equipment | 8 | 10 | 11 | 12 | 13 |
Investments & Advances | 0 | 2 | 12 | 0 | 15 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 3 | 3 | 3 | 5 |
Total Assets | 183 | 213 | 238 | 261 | 289 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 4 | 3 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 5 | 11 | 9 | 7 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9 | 10 | 9 | 9 | 10 |
Total Current Liabilities | 19 | 25 | 26 | 22 | 25 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 3 | 4 | 7 | 8 | 10 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 46 | 54 | 59 | 57 | 63 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 676 | 668 | 662 | 656 | 648 |
Retained Earnings | -539 | -509 | -484 | -452 | -422 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 137 | 159 | 179 | 203 | 226 |
Total Liabilities & Shareholder's Equity | 183 | 213 | 238 | 261 | 289 |
Total Common Equity | 137 | 159 | 179 | 203 | 226 |
Shares Outstanding | 60.00 | 58.30 | 58.30 | 57.60 | 57.60 |
Book Value Per Share | 2.28 | 2.73 | 3.06 | 3.53 | 3.92 |